

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Alemany Bonastre, Ramon, et al. Art Unit : Unknown  
Serial No. : 10/509,194 Examiner : Unknown  
Filed : September 23, 2004  
Title : USE OF ADENOVIRUSES MUTATED IN THE VA GENES FOR CANCER  
TREATMENT

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed within three months of the filing date of the application or before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

February 23, 2005

Mary Ann Dillahunty  
Mary Ann Dillahunty  
Reg. No. 34,576

Fish & Richardson P.C.  
500 Arguello Street, Suite 500  
Redwood City, California 94063  
Telephone: (650) 839-5070  
Facsimile: (650) 839-5071

50261240.doc

## CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV 322525462 US

February 24, 2005

Date of Deposit

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16596-049US1	Application No. 10/509,194
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Alemany Bonastre, Ramon, et al.	
		Filing Date September 23, 2004	Group Art Unit Unknown

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5002874	03/1991	Kaufman			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB	98/35028	08/1998	WO				
	AC	01/35970	05/2001	WO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AD	Alemany et al., "Replicative adenoviruses for cancer therapy", <i>Nature Biotechnology</i> 18, 723-727, 2000
	AE	Bergmann et al., "A genetically Engineered Influenza A Virus with <i>ras</i> -Dependent Oncolytic Properties", <i>Cancer Research</i> , 61: 8188-8193, 2001
	AF	Fowlkes et al., "Transcriptional Control Regions of the Adenovirus VAI RNA Gene" <i>Cell</i> 22, 405-413, 1980
	AG	Fueyo et al., "A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect <i>in vivo</i> ", <i>Oncogene</i> 19, 2-12, 2000
	AH	Gunnery et al. "Termination Sequence Requirements Vary among Genes Transcribed by RNA polymerase III" <i>Journal of Molecular Biology</i> 286 745-757, 1999
	AI	Ma et al. "Sturcture, Funcsion, and Evolution of Adenovirus-Associated RNA: a Phylogenetic Approach", <i>Journal of Virology</i> 70(8), 5083-5099, 1996
	AJ	Mundschau et al., "Oncogenic <i>ras</i> Induces an Inhibitor of Double-stranded RNA-dependent Eukaryotic Initiation Factor 2 $\alpha$ -kinase Activation", <i>Journal of Biological Chemistry</i> , 267(32): 23092-23098, 1992
	AK	Norman et al., "Reovirus as a novel oncolytic agent", <i>Journal of Clinical Investigation</i> 105: 1035-1038, 2000
	AL	Stojdl et al., "Exploiting tumor-specific defects in the interferonpathway with a previously unknown oncolytic virus", <i>Nature Medicine</i> 6(7): 821-825, 2000

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	